menopause and glp 1 The GLP-1/GIP dual-receptor agonist tirzepatide led to at least 15% loss of total body fat in premenopausal, perimenopausal, postmenopausal women, but postmenopausal women taking menopausal hormone therapy had the greatest weight Menopause and GLP-1 Weight Loss:

Potential therapeutic effects (based on animal and early human data): Enhances tendon, ligament, and muscle repair Promotes angiogenesis (formation of new blood vessels) Reduces inflammation and oxidative stress Protects gut mucosa and may aid in GI disorders (ulcers, leaky gut) May support neurological recovery and joint health Modulates nitric oxide and dopamine/serotonin pathways (possible mood, focus benefits) (Note: Most data are from preclinical studies

Obesity with hepatic steatosis : Patients with BMI 30 kg/m (or 27 kg/m with weight-related comorbidities) and documented fatty liver may benefit from GLP-1 agonists approved for chronic weight management

Start with a small amount and monitor for irritation before applying more regularly

Wesch, N., Lohr, F., Rogova, N., Dotsch, V

KCCYSL peptide and peptides containing KCCYSL sequence are specific peptides for human epidermal growth factor receptor 2 (HER2) overexpressed in breast cancer

The protocol works better